Registered outcomes12

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 12 of 12

List	Outcome	Time frame
Primary	The primary efficacy endpoint was the change from Baseline in hemoglobin (Hb)	12 Weeks
Secondary	Changes in other hematologic measurements	12 weeks
Secondary	Changes in RBC indices, including: mean corpuscular volume (MCV), mean corpuscular Hb concentration (MCHC), and mean corpuscular Hb (MCH	12 weeks
Secondary	Other laboratory measures associated with sickle cell crises activity including: direct and indirect bilirubin and lactic dehydrogenase (LDH)	12 weeks
Secondary	Rate of painful crises	12 weeks
Secondary	Time to first painful crisis	12 weeks
Secondary	Morbidity of painful crises (maximum morbidity index, derived variable)	12 weeks
Secondary	Pain intensity scores	12 weeks
Secondary	Quality of Life (SF 36)	12 Weeks
Secondary	Health economic data	12 weeks
Secondary	Average plasma concentration	12 weeks
Secondary	Correlation between the average plasma concentration and the change in Hb from Baseline to study endpoint	12 weeks

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00040677/registered